FIBRINOLYSIS AND HEMORHEOLOGY IN CHRONIC VENOUS INSUFFICIENCY - A DOUBLE-BLIND-STUDY OF TROXERUTIN EFFICIENCY

Abnormal increase of erythrocyte aggregation and reduction of profibri nolytic activity are the two most frequent biological perturbations fo und in chronic venous insufficiency (CVI). A randomised, controlled, d ouble blind trial was undertaken on 85 patients suffering from grade 1 and 2 CVI, to compare troxerutin with placebo. Two types of biologica l parameters were measured after 15 days of treatment. Erythrocy-te ag gregation as evaluated with a Myrenne erythroaggregometer by the indic es M (stasis) and M1 (3s(-1)) progressed favorably in the troxerutin g roup. The values of M1 at D15 (p<0.05), and the progression of M (p<0. 001) and M1 (p<0.01) from D0 to D15, are significantly better in the t roxerutin group, Progression of fibrinolytic activity at rest was not significantly different between the 2 groups. Conversely, the progress ion from D0 to D15 of the values after occlusion of euglobulin lysis t ime (p<0.01), tPA (p<0.01), and PAI activity (p<0.05) are significantl y better in the troxerutin group. The fibrinolysis capacity estimated by euglobulin lysis time (p<0.01) and tPA (p<0.05) also progressed fav orably in the troxerutin group. These results confirm the anti-erythro cyte aggregation effect of troxerutin, and suggest a favorable effect on blood fibrinolytic activity. They could explain the positive action of this drug on stasis, capillary perfusion and trophic complications of CVI.